Kelly M. Brooks

Kelly M. Brooks

Auto-generated profile, based on publicly available information

Kelly M. Brooks

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
FNFelicity Newell
Felicity Newell
PJPeter A. Johansson
Peter A. Johansson
JWJames Wilmott
James Wilmott
Katia NonesKatia Nones
Katia Nones
VLVanessa Lakis
Vanessa Lakis
Nicholas K. HaywardNicholas K. Hayward
Nicholas K. Hayward
Melanoma is a cancer of melanocytes, with multiple subtypes based on body site location. Cutaneous melanoma is associated with skin exposed to ultraviolet radiation; uveal melanoma occurs in the eyes; mucosal melanoma occurs in internal mucous membranes; and acral melanoma occurs on the palms, soles, and nail beds. Here, we present the largest whole-genome sequencing study of melanoma to date, with 570 tumors profiled, as well as methylation and RNA sequencing for subsets of tumors. Uveal melanoma is genomically distinct from other melanoma subtypes, harboring the lowest tumor mutation burden and with significantly mutated genes in the G-protein signaling pathway. Most cutaneous, acral, and mucosal melanomas share alterations in components of the MAPK, PI3K, p53, p16, and telomere pathways. However, the mechanism by which these pathways are activated or inactivated varies between melanoma subtypes. Additionally, we identify potential novel germline predisposition genes for some of the less common melanoma subtypes. Significance: This is the largest whole-genome analysis of melanoma to date, comprehensively comparing the genomics of the four major melanoma subtypes. This study highlights both similarities and differences between the subtypes, providing insights into the etiology and biology of melanoma. This article is highlighted in the In This Issue feature, p. 2711

5 March 2012 in Oncogene
Verified
Journal Article
Open access
PDF file
KBK Brooks
K Brooks
VOV Oakes
V Oakes
BEB Edwards
B Edwards
MRM Ranall
M Ranall
PLP Leo
P Leo
Brian GabrielliBrian Gabrielli
Brian Gabrielli
There are few effective treatments for metastatic melanoma. Checkpoint kinase 1 (Chk1) inhibitors are being trialled for their efficacy in enhancing conventional chemotherapeutic agents, but their effectiveness as single agents is not known. We have examined the effectiveness of two novel Chk1 selective inhibitors, AR323 and AR678, in a panel of melanoma cell lines and normal cell types. We demonstrate that these drugs display single-agent activity, with IC50s in the low nanomolar range. The drugs produce cytotoxic effects in cell lines that are most sensitive to these drugs, whereas normal cells are only sensitive to these drugs at the higher concentrations where they have cytostatic activity. The cytotoxic effect is the consequence of inhibition of S-phase Chk1, which drives cells prematurely from late S phase into an aberrant mitosis and results in either failure of cytokinesis or cell death through an apoptotic mechanism. The sensitivity to the Chk1 inhibitors was correlated with the level of endogenous DNA damage indicating replicative stress. Chk1 inhibitors are viable single-agent therapies that target melanoma cells with high levels of endogenous DNA damage. This sensitivity suggests that Chk1 is a critical component of an adaptation to replicative stress in these cells. It also suggests that markers of DNA damage may be useful in identifying the melanomas and potentially other tumour types that are more likely to be sensitive to Chk1 inhibitors as single agents.

1 January 2012 in Frontiers in Pharmacology
Verified
Journal Article
Open access
Brian GabrielliBrian Gabrielli
Brian Gabrielli
KBKelly Brooks
Kelly Brooks
SPSandra Pavey
Sandra Pavey
Conventional chemotherapeutics target the proliferating fraction of cells in the patient’s body, which will include the tumor cells, but are also toxic to actively proliferating normal tissues. Cellular stresses, such as those imposed by chemotherapeutic drugs, induce cell cycle checkpoint arrest, and currently approaches targeting these checkpoints are being explored to increase the efficacy and selectivity of conventional chemotherapeutic treatments. Loss of a checkpoint may also make cancer cells more reliant on other mechanisms to compensate for the loss of this function, and these compensatory mechanisms may be targeted using synthetic lethal approaches. Here we will discuss the utility of targeting checkpoint defects as novel anti-cancer therapies.

4 February 2019 in Immunogenetics
Verified
Journal Article
Closed access
PDF file
PJPeter A. Johansson
Peter A. Johansson
ASAndrew Stark
Andrew Stark
JPJane M. Palmer
Jane M. Palmer
KBKieron Bigby
Kieron Bigby
KBKelly Brooks
Kelly Brooks
Nicholas K. HaywardNicholas K. Hayward
Nicholas K. Hayward

6 December 2010 in Oncogene
Verified
Journal Article
Open access
PDF file
CSC E Smart
C E Smart
AWA Wronski
A Wronski
JFJ D French
J D French
Stacey EdwardsStacey Edwards
Stacey Edwards
MAM-L Asselin-Labat
M-L Asselin-Labat
MBM A Brown
M A Brown
Disruption of the breast cancer susceptibility gene Brca1 results in defective lobular-alveolar development in the mammary gland and a predisposition to breast tumourigenesis in humans and in mice. Recent evidence suggests that BRCA1 loss in humans is associated with an expansion of the luminal progenitor cell compartment in the normal breast and tumours with a luminal progenitor-like expression profile. To further investigate the role of BRCA1 in the mammary gland, we examined the consequences of Brca1 loss in mouse mammary epithelial cells in vitro and in vivo. Here, we show that Brca1 loss is associated with defective morphogenesis of SCp2 and HC11 mouse mammary epithelial cell lines and that in the MMTV-Cre Brca1Co/Co mouse model of Brca1 loss, there is an accumulation of luminal progenitor (CD61+CD29loCD24+) cells during pregnancy. By day 1 of lactation, there are marked differences in the expression of 1379 genes, with most significantly altered pathways and networks, including lactation, the immune response and cancer. One of the most differentially expressed genes was the luminal progenitor marker, c-kit. Immunohistochemical analysis revealed that the increase in c-kit levels is associated with an increase in c-kit positivity. Interestingly, an inverse association between Brca1 and c-kit expression was also observed during mammary epithelial differentiation, and small interfering RNA-mediated knockdown of Brca1 resulted in a significant increase in c-kit mRNA levels. We found no evidence that c-kit plays a direct role in regulating differentiation of HC11 cells, suggesting that Brca1-mediated induction of c-kit probably contributes to Brca1-associated tumourigenesis via another cellular process, and that c-kit is likely to be a marker rather than a mediator of defective lobular-alveolar development resulting from Brca1 loss.

1 January 2014 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KBKelly Brooks
Kelly Brooks
KCKee Ming Chia
Kee Ming Chia
LSLoredana Spoerri
Loredana Spoerri
PMPamela Mukhopadhyay
Pamela Mukhopadhyay
MWMatthew Wigan
Matthew Wigan
Brian GabrielliBrian Gabrielli
Brian Gabrielli